METHODS FOR TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR Russian patent published in 2021 - IPC A61K38/02 A61P17/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine, namely immunology and dermatology, and is intended for reducing itching and treating atopic dermatitis (AtD). The method for reducing itching, or treating atopic dermatitis (AtD), or improving at least one AtD-associated indicator includes (a) selecting a patient with moderate/severe AtD, who is a candidate for systemic therapy, wherein the patient has a history of inappropriate response or intolerance to a systemic immunosuppressive agent and/or wherein the therapy with a systemic immunosuppressive agent is not recommended; and (b) administering a therapeutically effective amount of a pharmaceutical composition including an interleukin-4 receptor (IL- 4R) inhibitor to the patient. The IL-4R inhibitor constitutes an antibody or an antigen-binding fragment thereof, binding IL-4R. The antibody or the antigen-binding fragment thereof include three HCDR areas (HCDR1, HCDR2 and HCDR3) and three LCDR areas (LCDR1, LCDR2 and LCDR3), wherein HCDR1 includes the amino acid sequence SEQ ID NO: 3; HCDR2 includes the amino acid sequence SEQ ID NO: 4; HCDR3 includes the amino acid sequence SEQ ID NO: 5; LCDR1 includes the amino acid sequence SEQ ID NO: 6; LCDR2 includes the amino acid sequence SEQ ID NO: 7 and LCDR3 includes the amino acid sequence SEQ ID NO:8. In another implementation, an application of the described IL-4R inhibitor in reducing itching, or treatig atopic dermatitis (AtD), or improving at least one AtD-associated indicator in a patient with moderate/severe AtD, who is a candidate for systemic therapy, is provided. in another implementation. an application of the IL-4R inhibitor in production of a medicinal product for reducing itching, or treating atopic dermatitis (AtD), or improving at least one AtD-associated indicator in a patient with moderate/severe AtD, and who is a candidate for systemic therapy, is provided. Also presented is an application of a pharmaceutical composition for reducing itching, or treating atopic dermatitis (AtD), or improving at least one AtD-associated indicator in a patient with moderate/severe AtD, who is a candidate for systemic therapy, wherein the patient has had an event of inappropriate response or intolerance to a systemic immunosuppressive agent and/or wherein therapy with a systemic immunosuppressive agent is not recommended, wherein the composition includes a therapeutically effective amount of the described IL-4R inhibitor.

EFFECT: use of the group of inventions provides a possibility of increasing the effectiveness of treatment of atopic dermatitis.

35 cl, 10 tbl, 8 ex